Hemolytic-uremic syndrome future or investigational therapies

Hemolytic-uremic syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hemolytic-uremic syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hemolytic-uremic syndrome future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hemolytic-uremic syndrome future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hemolytic-uremic syndrome future or investigational therapies
CDC on Hemolytic-uremic syndrome future or investigational therapies
Hemolytic-uremic syndrome future or investigational therapies in the news
Blogs on Hemolytic-uremic syndrome future or investigational therapies
Directions to Hospitals Treating Hemolytic-uremic syndrome
Risk calculators and risk factors for Hemolytic-uremic syndrome future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Sogand Goudarzi, MD [2]

Future or Investigational Therapies

• ASA and dipyridamole not effective alone,benefit when added to plasma exchange
• In poorly responsive or resistant disease, INCREASE PLASMA EXCHANGE
• Then consider:

• prednisone (1 mg/kg per day)
• methylprednisolone (125 mg IV bid)
• Vincristine
• IVIG